<p>Metadon je sintetski agonist opijatnih receptora koji se primenjuje u sklopu supstitucione terapije opijatnih zavisnika metadonom (STM) i u terapiji hroničnog bola. Dugoročna primena STM je praćena blagim, uglavnom prolaznim, neželjenim delovanjima. Međutim, metadon pripada grupi lekova koji mogu da prouzrokuju prolongaciju korigovanog QT intervala (QTc) u elektrokardiogramu (EKG-u) i povećaju rizik za nastanak potencijalno fatalnih aritmija tipa torsades de pointes. Opijatni zavisnici metadon najče&scaron;će koriste u kombinaciji sa benzodiazepinima, i ova kombinacija lekova predstavlja faktor rizika za nastanak smrtnog ishoda. Iako je najveći broj lekara upoznat sa rizikom za razvoj respiratorne depresije prilikom primene opijata u kombinacji sa benzodiazepinima, velika studija otkriva da su ventrikularne aritmije i srčani zastoj najče&scaron;će prijavljivana neželjena delovanja metadona, primenjenog u kombinaciji sa benzodiazepinima. Ciljevi ovoga radu su da se analizom smrtnih slučajeva povezanih sa upotrebom metadona (MRDs) tokom desetogodi&scaron;njeg perioda na teritoriji Vojvodine i sprovođenjem kliničkog ispitivanja kod opijatnih zavisnika na STM proceni kardiolo&scaron;ka bezbednost primene metadona, posebno u kombinaciji sa benzodiazepinima. Sprovedena je retrospektivna studija za određivanje karakteristika MRDs na teritoriji Vojvodine, kao i kliničko ispitivanje u kome su učestvovali opijatni zavisnici koji počinju sa STM. Snimanje EKG-a (za izračunavanje QTc intervala) i uzorkovanje krvi (za određivanje koncentracije metadona i diazepama i vrednosti troponina) je sprovedeno kod svih učesnika istraživanja u 5 vremenskih tačaka (pre početka primene STM, 8. i 15. dana i nakon 1. i 6. meseca primene STM). Koncentracije metadona i diazepama u serumu su određivane metodom tečne hromatografije sa masenom spektrometrijom (LC-MS). U Vojvodini je zapažena rastuća tendencija MRDs, ali ni jedan od umrlih nije bio na STM, i najverovatnije su samoinicijativno koristili metadon i benzodiazepine. Patohistolo&scaron;ki nalaz na srcu može govoriti u prilog kardiotoksičnosti metadona i njegove kombinacije sa benzodiazepinima, pogotovo kod slučajeva sa pronađenim akutnim miokardijalnim o&scaron;tećenjem. &Scaron;to se tiče hroničnih promena na srcu, ne postoji mogućnosti da se potvrdi niti opovrgne uloga psihostimulanasa. Detektovane koncentracije metadona i diazepama kod MRDs su bile u opsegu terapijskih (&lt;1 &mu;g/ml). Poredeći socio-demografske karakteristike opijatnih zavisnika koji su počeli sa STM u ovom istraživanju sa podacima iz sličnih studija sprovedenih &scaron;irom sveta, zapažena je sličnost u pogledu velikog broja karakteristika. Srednje doze metadona 8., 15. dana i nakon 1. i 6. meseca primene STM su bile 40,23&plusmn;17,11 mg, 47,11&plusmn;16,79 mg, 50,00&plusmn;17,55 mg i 78,63&plusmn;18,14 mg, dok su srednje doze diazepama u istim vremenskim tačkama bile 35,92&plusmn;10,47 mg, 33,89&plusmn;9,23 mg, 28,33&plusmn;11,55 mg i 28,12&plusmn;11,67 mg. Srednje koncentracije metadona su u posmatranim tačkama ispitivanja iznosile 153,44&plusmn;111,51 ng/ml, 157,43&plusmn;112,39 ng/ml, 176,77&plusmn;118,56 ng/ml i 342,86&plusmn;181,54 ng/ml, dok su srednje koncentracije diazepama bile 923,00&plusmn;537,89 ng/ml, 923,76&plusmn;739,96 ng/ml, 560,74&plusmn;436,72 ng/ml i 1045,32&plusmn;932,72 ng/ml. Dužina QTc intervala pre primene STM je bila 411,87&plusmn;27,22 ms, tj. 414,64&plusmn;29,38 ms 8. dana STM, 416,97&plusmn;26,39 15. dana, i 425,20&plusmn;17,71 ms nakon 1. meseca tj. 423,50&plusmn;14,72 ms nakon 6. meseca primene STM. Pokazan je statistički značajan porast dužine QTc intervala nakon 1. i nakon 6. meseca primene STM u odnosu na vrednost pre primene STM, kako u grupi svih ispitanika, tako i u podgrupi mu&scaron;kog pola. Pokazano je postojanje statistički značajne korelacije između koncentracije metadona i dužine QTc intervala nakon 15. dana, 1. i 6. meseca primene STM, kako kod svih ispitanika, tako i u podgrupi mu&scaron;kog pola. Ova korelacija ostaje statistički značajna i ukoliko se uključe i drugi faktori &ndash; koncentracija diazepama i dužina perioda upotrebe heroina, kod svih ispitanika i u podgrupi mu&scaron;kog pola nakon 15 dana i mesec dana primene STM, kao i u podgrupi mu&scaron;kog pola nakon 6. meseca STM. Iako nijedan pacijent nije prijavio neko neželjeno delovanje metadona na nivou kardiovaskularnog sistema, najveći broj pacijenata oba pola se nakon prvog meseca primene STM žalio na pojačano znojenje i opstipaciju. Koncentracije metadona i diazepama u uzorcima krvi kod MRDs se nalaze u rasponu koncentracija ovih lekova u krvi ispitanika koji su učestvovali u prospektivnoj studiji. Trećina umrlih je imala samo znake akutnog o&scaron;tećenja srca, dok do porasta troponina i vrednosti QTc intervala preko 500 ms nije do&scaron;lo ni kod jednog ispitanika iz prospektivne studije. Potrebno je sprovesti dalja istraživanja sa ciljem razja&scaron;njenja moguće uloge benzodiazepina u povećanju kardiotoksičnosti metadona kod opijatnih zavisnika na STM.</p> / <p>Methadone is a synthetic agonist of opioid receptors which is used in methadone maintenance tratment (MMT) of opiate addicts as well as in the treatment of chronic pain. A long-term use of MMT is followed by mild, mostly transient, adverse effects. However, methadone belongs to a group of medicines which can provoke a prolongation of QTc (corrected QT) interval in electrocardiogram (ECG) and thus increase the risk from the development of potentially fatal arrhythmias &ndash; torsades de pointes. Moreover, methadone is widely associated with benzodiazepines use in heroin addicts, and this combination is considered as a risk factor for lethal outcome. Despite the fact that most of health care professionals are aware of possible respiratory depressant effect of methadone and benzodiazepines co-administration, recently published data reveal that ventricular arrhythmia and cardiac arrest are currently the most frequent adverse event attributed to methadone and benzodiazepine co-medication. The aim of this study is to assess cardiac safety of methadone use, especially in combination with benzodiazepines, by analyzing characteristics of methadone-related deaths (MRDs) during 10-year period as well as by conducting a clinical trial among opiate addicts in MMT. A retrospective study to determine the characteristics of MRDs in Vojvodina, as well as a clinical trial in which participated opiate addicts at the start of MMT were performed. ECG (to calculate QTc interval) and blood sampling (to determine methadone and diazepam concentrations and troponin values) were performed in all study participants at five time points (before the introduction of MMT, on 8th, on 15th day, after 1 and 6 months of MMT). Methadone and diazepam concentrations in serum were determined by using liquid chromatography-mass spectrometry (LC-MS). An increasing tendency of MRDs was observed in the region of Vojvodina, but none of the victims were under healthcare professionals&rsquo; control, and, most commonly, they used methadone and benzodiazepines, on their own initiative. Pathohistological findings in the heart in MRDs might support cardiac adverse effects of methadone and its combination with benzodiazepines, especially in cases with acute myocardial damage. As for the chronic heart changes, we can neither confirm nor exclude the role of psychostimulants. Detected concentrations of methadone and diazepam were in therapeutic range (&lt;1 &mu;g/ml). Comparing socio-demographic characteristics of opiate addicts who started with MMT in this study with data from similar studies conducted worldwide, the similarity in terms of large number of features was observed. The mean methadone dose on the 8th, 15th days, and after 1 and 6 months of MMT was 40.23&plusmn;17.11 mg, 47.11&plusmn;16.79 mg, 50.00&plusmn;17.55 mg and 78.63&plusmn;18.14 mg, respectively, while the mean diazepam dose at the same time points was 35.92&plusmn;10.47 mg, 33.89&plusmn;9.23 mg, 28.33&plusmn;11.55 mg and 28.12&plusmn;11.67 mg, respectively. The mean methadone concentration at observed time points was 153.44&plusmn;111.51 ng/ml, 157.43&plusmn;112.39 ng/ml, 176.77&plusmn;118.56 ng/ml and 342.86&plusmn;181.54 ng/ml, respectively, while the mean diazepam concentration was 923.00&plusmn;537.89 ng/ml, 923.76&plusmn;739.96 ng/ml, 560.74&plusmn;436.72 ng/ml and 1045.32&plusmn;932.72 ng/ml, respectively. The length of QTc interval before the introduction of MMT was 411.87&plusmn;27.22 ms, 414.64&plusmn;29.38 ms on the 8th day of MMT, 416.97&plusmn;26.39 on the 15th day of MMT, after 1 month of MMT 425.20&plusmn;17.71 ms and after 6 months of MMT 423.50&plusmn;14.72 ms. There was a statistically significant increase in the length of QTc interval after 1 and 6 months of MMT in comparison to the value before the application of MMT, within the whole group of patients and in the subgroup of men. A statistically significant correlation between the concentration of methadone and QTc interval length after 15 days, 1 and 6 months of MMT, both in the whole group and in the subroup of men was observed. The correlation remained statistically significant if the other factors, such as concentration of diazepam and the length of heroin use, were included, in all patients and in the subgroup of men after 15 days and one month of MMT as well as in the subgroup of men after 6 months of MMT. Although none of the patients reported any cardiac adverse effect of methadone, the majority of them complained of sweating and constipation after the first month of MMT. Concentrations of methadone and diazepam in blood samples in MRDs were within the range of concentrations of these drugs in blood of patients who participated in the prospective study. In one third of MRDs only signs of acute myocardial damage were detected, while an increase in troponin values and the length of QTc interval over 500 ms did not occur in any patient in the prospective study. Further studies could clarify the possible role of benzodiazepines in the increasing cardiotoxicity of methadone in opiate addicts in MMT.</p>

Die ersten identifizierten Krankheitsgene der dilatativen Kardiomyopathie (DCM) kodierten alle für Proteine des Zytoskeletts. Deshalb wurde DCM als Erkrankung des Zytoskeletts bezeichnet. Bei der hypertrophen Kardiomyopathie (HCM) wurden bisher mehr als 250 Mutationen in neun Sarkomerprotein-Genen beschrieben. Deshalb wurde HCM als Erkrankung des Sarkomers bezeichnet. In den letzten Jahren wurde dieses Konzept durch Entdeckung von Mutationen in Sarkomerprotein-Genen bei DCM jedoch in Frage gestellt. Vor diesem Hintergrund haben wir die Sarkomerprotein-Gene beta-MHC und Troponin T bei 46 nicht verwandten DCM-Patienten untersucht. Das systematische Mutationsscreening wurde mit Hilfe von SSCP-Analyse und DNA-Sequenzierung durchgeführt. Im beta-MHC-Gen konnten wir die zwei Missense-Mutationen Ala223Thr und Ser642Leu bei zwei jungen Patienten identifizieren. Beide Mutationen wurden weder bei 136 HCM-Patienten noch bei 88 Kontrollen gefunden. Mit dem Editor for Structural Alignment of Proteins (STRAP) wurden die Mutationen auf die Proteinstruktur des Myosins projiziert. Hier ist erkennbar, dass Ala223Thr in der oberen 50 kDa Domäne und Ser642Leu in der Aktin-Myosin-Bindungsregion liegt. Der Austausch von Alanin zu Threonin könnte die Raumstruktur des Proteins verändern, Thermostabilität verringern und die Proteinfaltung und somit die Proteinmotilität beeinträchtigen. In der Aktin-Myosin-Bindungsregion liegt neben Ser642Leu die bereits bekannte DCM-assoziierte Mutation Ser532Pro. Durch eine Verminderung der Krafterzeugung könnten die beiden Mutationen zu DCM führen. Ferner wurden die zwei stummen Mutationen IVS11+23A>T und Asp376Asp und sechs Polymorphismen identifiziert. Im Troponin T-Gen wurden keine Mutationen, jedoch sechs Polymorphismen beobachtet. Es ergab sich kein Anhaltspunkt auf eine funktionelle Relevanz der stummen Mutationen oder Polymorphismen. Wir konnten also bestätigen, dass Mutationen in Sarkomerprotein-Genen sowohl zu HCM als auch zu DCM führen können. / All of the initially identified disease-causing genes in dilated cardiomyopathy (DCM) encoded proteins of the cytoskeleton. Therefore DCM has been termed a disease of the cytoskeleton. In hypertrophic cardiomyopathy (HCM) more than 250 mutations in nine sarcomeric protein genes have been identified so far. Therefore HCM has been termed a disease of the sarcomere. However, in the last few years this concept has been queried by findings of mutations in sarcomeric protein genes in DCM. According to this consideration we screened the sarcomeric protein genes beta-MHC and troponin T in 46 patients with DCM. Systematic mutation screening was done using SSCP analysis and DNA sequencing. In the beta-MHC gene we identified the two missense mutations Ala223Thr and Ser642Leu in two young patients. Both mutations were neither found in 136 HCM patients nor in 88 controls. Using the Editor for Structural Alignment of Proteins (STRAP) the mutations were projected onto the protein structure of myosin. Ala223Thr turned out to be localized in the upper 50 kDa domain and Ser642Leu in the actin-myosin-interface region. The exchange from alanine to threonine might alter the spatial structure of the protein, decrease its thermostability and affect the protein folding and thus the protein motility. Closely to Ser642Leu the DCM-associated mutation Ser532Pro is located in the actin-myosin-interface region. By a decrease in force production both mutations might cause DCM. Furthermore we identified the two silent mutations IVS11+23A>T and Asp376Asp and six polymorphisms. In the troponin T gene no mutations but six polymorphisms were detected. No evidence was found for functional relevance of the silent variants or polymorphisms. Thus, we could confirm that mutations in sarcomeric protein genes can lead to both HCM and DCM.

Les films de simulations qui accompagnent le document ont été réalisés avec Pymol. / Les protéines accomplissent leur fonction dans la cellule grâce à leur faculté de changer de forme. Chaque classe de protéines peut se caractériser par une structure spécia- lisée partagée par ses membres avec un certain degré de variabilité. Tel est le cas des protéines à motifs mains-EF, qui se transforment en liant et déliant l ’ion calcium. Ce motif permet à la Troponin C de s’ouvrir et se refermer afin de moduler le mécanisme de contraction des fibres musculaires. Un mécanisme similaire permet à la Calmoduline de gérer l’activité de divers canaux cellulaires. Les techniques de simulations numériques peuvent aider à comprendre les trajectoires de ces transformations. Le projet principal de cette thèse consistait à développer une méthode informatique multi-échelle permettant de simuler des mouvements complexes à l’intérieur d ’une protéine. La représentation multi-échelle développée peut changer et s’adapter en cours de simulation. La méthode, ART holographique, explore l’espace en générant des basculements d’ensembles atomiques, selon des champs de force atomistiques non biaisés indiquant à tout moment comment les ensembles doivent pivoter. La méthode réduit le calcul des fluctuations locales mais conserve une représentation spatiale complète. La représentation multi-échelle est combinée à une technique de recherche de passages de transition énergétiquement favorables, ART nouveau, qui conduit la trajectoire moléculaire d ’étape en étape. Appliquée à plusieurs protéines, dont la Calmodulin et la Troponin C, ART holographique génère des trajectoires de transformation entre des conformations distantes de celles-ci, déjà connues grâce aux techniques de RMN ou de cristallographie. L’usage d ’une représentation spatiale complète tout au long de la simulation favorise le discernement de certains détails des mécanismes. Le rôle, l’ordre d ’intervention, ainsi que la coopérativité de certains résidus et structures impliqués dans le mécanisme des paires main-EF ont été explorés plus en détail et un état intermédiaire est proposé. / Proteins accomplish their function inside cells by means of conformational changes. Each protein class may be characterized by a specialized structure shared by its members with some variability. EF-hands proteins present a special motif which transforms itself while binding or unbinding the calcium ion. This structure allows Troponin C domains to open and close as it modulates the muscular fibers contraction. A similar mechanism allow Calmodulin to manage the activity of a diversity of protein channels. Computational techniques may help discover how these transformations occur. The main project of this thesis was the development of a multi-scale computational method for the simulation of complex motions inside a protein. The multi-scale approach is designed to adapt and change all along the simulation. The method, holographic ART, explore conformational space by generating swiveling and rotation of atomic ensembles, leaded by non biased atomistic forcefields. This determines at each step the overall motion, keeping a complete spatial representation, but with minimal local fluctuations computation. The multi-scale representation is combined with a unbiased open ended algorithm for identifying transitions states, ART nouveau, which guides the molecular trajectory from state to state. Applied to several proteins, the method was able to generate transforma- tion trajectories between distant conformations known from NMR and crystallography techniques. The use of a complete spatial representation throughout the simulation allows the method to capture atomistic details of each event. The purpose, the intervention order, as well as cooperativity between some residues and sub-structures involved in the EF-hand pair mechanism have been explored more in detail and an intermediate state is proposed.

Introdução: O tratamento quimioterápico com antraciclina está associado à cardiotoxicidade. Sua prevenção primária com o uso de beta-bloqueadores permanece controversa. O objetivo do presente estudo é avaliar o papel do carvedilol na prevenção da cardiotoxicidade relacionada ao tratamento com antraciclina. Métodos: estudo randomizado, duplo-cego, placebo controlado que incluiu 200 pacientes com câncer de mama, fração de ejeção ventricular esquerda (FEVE) preservada e uso de doxorrubicina (240 mg/m²) para receber carvedilol ou placebo até a conclusão da quimioterapia em proporção 1:1. O desfecho primário foi a redução > 10% da FEVE em seis meses. Os desfechos secundários foram o efeito do carvedilol nos marcadores de injúria miocárdica, troponina I (TnI) e peptídeo natriurético cerebral (BNP), e na disfunção diastólica. Resultados: O desfecho primário ocorreu em 14 (14,5%) pacientes do grupo carvedilol e em 13 (13,5%) do grupo placebo (p=1,0). Não houve diferença nos valores da FEVE durante o tratamento quimioterápico ou nos valores de BNP entre os grupos. Houve diferença significativa entre os grupos na distribuição dos níveis de TnI ao longo do tempo, com menor pico de TnI no grupo carvedilol (p=0,003). Além disso, houve menor incidência de disfunção diastólica no grupo carvedilol (p=0,039). Foi observada tendência para menor aumento do diâmetro diastólico do ventrículo esquerdo do início do tratamento até o final da quimioterapia no grupo carvedilol em relação ao placebo, respectivamente, 44,1+3,64 a 45,2+3,2 vs 44,9+3,6 a 46,4+4,0 mm (p=0,057). Conclusão: A incidência de cardiotoxicidade com o uso de doses contemporâneas de ANT foi menor do que relatado previamente com doses mais elevadas. Neste cenário, a administração de carvedilol resultou em redução significativa da injúria miocárdica avaliada pelos níveis de troponina I e pelo aparecimento da disfunção diastólica. No entanto, essa redução não teve impacto na disfunção sistólica relacionada à cardiotoxicidade (NCT01724450) / Background: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Its prevention with beta-blockers remains controversial. The aim of this prospective, randomized, double-blind, placebo-controlled study was to evaluate the role of carvedilol in the prevention of early onset ANT cardiotoxicity. Methods: We randomized 200 patients with breast cancer and normal left ventricular ejection fraction (LVEF) referred for doxorubicin (240 mg/m²) to receive carvedilol or placebo until completion of chemotherapy. The primary end-point was a reduction > 10% in LVEF at six months. Secondary outcomes were the effects of carvedilol on troponin I (TnI), BNP and diastolic dysfunction. Results: Primary end-point occurred in 14 (14.5%) patients in the carvedilol and in 13 (13.5%) in the placebo (p=1.0). No difference in changes of LVEF or BNP was noted between groups. There was a significant difference between groups on the TnI levels over time, with lower TnI levels in carvedilol group (p=0.003). Additionally, a lower incidence of diastolic dysfunction was seen in carvedilol group (p=0.039). A trend towards less pronounced increase in LV end-diastolic diameter during follow up was noted in the carvedilol group, respectively 44.1+3.64 to 45.2+3.2 vs 44.9+3.6 to 46.4+4.0 mm (p=0.057). Conclusion: In this largest clinical trial of ?-blockers for prevention of early onset cardiotoxicity under contemporary doses of ANT, we noted a lower incidence of cardiotoxicity than higher doses. In this scenario, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction. However, this reduction had no impact on the incidence of cardiotoxicity-related myocardial systolic dysfunction (NCT01724450)

O complexo troponina-tropomiosina regula a contração muscular esquelética e cardíaca. A ligação do cálcio nos sítios regulatórios localizados no domínio N-terminal da troponina C (TnC) induz uma mudança conformacional que remove a ação inibitória da troponina I (TnI) e inicia a contração muscular. Nós usamos fragmentos recombinantes da TnI e uma série de mutantes da TnC para estudar as interações estruturais e regulatórias das diferentes regiões da TnI com os domínios da TnC, TnT e actina-tropomiosina. Nossos resultados indicam que a TnI é organizada em regiões que apresentam funções estruturais e regulatórias e que se ligam de modo antiparalelo com os correspondentes domínios estruturais e regulatórios da TnC. Estudos funcionais mostram que a região inibitória (aminoácidos 103-116) em combinação com a região C-terminal da TnI (TnI103-182) pode regular a atividade ATPásica da acto-miosina de maneira dependente de Ca2+. A regulação não é observada com a região inibitória em combinação com a região N-terminal (TnI116) Estudos de ligação mostram que a região N-terminal da TnI (TnI1-98) interage com o domínio C-terminal da TnC na presença e na ausência de Ca2+ e também interage com a TnT. A região inibitória/C-terminal da TnI (TnI103-182) interage com o domínio N-terminal da TnC de maneira dependente de Ca2+. Baseados nestes resultados, propomos um modelo para a mudança conformacional induzida pelo Ca2+. Neste modelo, a região N-terminal da TnI está ligada fortemente com o domínio C-terminal da TnC na presença ou na ausência de Ca2+. As regiões inibitórias e C-terminal da TnI ligam-se à actina-tropomiosina na ausência de Ca2+ e nos domínios N-terminal e C-terminal da TnC na presença de Ca2+. / The troponin-tropomyosin complex regulates skeletal and cardiac muscle contraction. Calcium binding to the regulatory sites in the N-terminal domain of troponin C (TnC). induces a conformational change which removes the inhibitory action of troponin I (TnI) and initiates muscular contraction. We used recombinant TnI fragments and a series of TnC mutants to study the structural and regulatory interactions between different TnI regions and the domains of TnC, TnT and actin-tropomyosin. Our results indicate that TnI is organized into regions with distinct structural and regulatory functions which bind, in an antiparallel manner, with the corresponding structural and regulatory domains of TnC. Functional studies show that a fragment containing the inhibitory and C-terminal regions of TnI (TnIl03-182) can regulate the actomyosin ATPase in a Ca2+- dependent manner. Regulation was not observed with a fragment containing the N-terminal and inhibitory regions (TnIl-116). Binding studies show that the N-terminal region of TnI (TnI1-98) interacts with the C-terminal domain of TnC in the presence of Ca2+ or Mg2+. The inhibitory/C-terminal region of TnI (TnI103-182) binds to the N-terminal domain of TnC in a Ca2+-dependent manner. Based on these results, we propose a model for the Ca2+ -induced conformational change. In this model the N-terminal region of TnI is bound strongly to the C-terminal domain of TnC in the presence or absence of Ca2+. The inhibitory and C-terminal regions of TnI bind to actin-tropomyosin in the absence of Ca2+ and to tne N- and C-terminal domains of TnC in the presence of Ca2+.

Introdução: O tratamento quimioterápico com antraciclina está associado à cardiotoxicidade. Sua prevenção primária com o uso de beta-bloqueadores permanece controversa. O objetivo do presente estudo é avaliar o papel do carvedilol na prevenção da cardiotoxicidade relacionada ao tratamento com antraciclina. Métodos: estudo randomizado, duplo-cego, placebo controlado que incluiu 200 pacientes com câncer de mama, fração de ejeção ventricular esquerda (FEVE) preservada e uso de doxorrubicina (240 mg/m²) para receber carvedilol ou placebo até a conclusão da quimioterapia em proporção 1:1. O desfecho primário foi a redução > 10% da FEVE em seis meses. Os desfechos secundários foram o efeito do carvedilol nos marcadores de injúria miocárdica, troponina I (TnI) e peptídeo natriurético cerebral (BNP), e na disfunção diastólica. Resultados: O desfecho primário ocorreu em 14 (14,5%) pacientes do grupo carvedilol e em 13 (13,5%) do grupo placebo (p=1,0). Não houve diferença nos valores da FEVE durante o tratamento quimioterápico ou nos valores de BNP entre os grupos. Houve diferença significativa entre os grupos na distribuição dos níveis de TnI ao longo do tempo, com menor pico de TnI no grupo carvedilol (p=0,003). Além disso, houve menor incidência de disfunção diastólica no grupo carvedilol (p=0,039). Foi observada tendência para menor aumento do diâmetro diastólico do ventrículo esquerdo do início do tratamento até o final da quimioterapia no grupo carvedilol em relação ao placebo, respectivamente, 44,1+3,64 a 45,2+3,2 vs 44,9+3,6 a 46,4+4,0 mm (p=0,057). Conclusão: A incidência de cardiotoxicidade com o uso de doses contemporâneas de ANT foi menor do que relatado previamente com doses mais elevadas. Neste cenário, a administração de carvedilol resultou em redução significativa da injúria miocárdica avaliada pelos níveis de troponina I e pelo aparecimento da disfunção diastólica. No entanto, essa redução não teve impacto na disfunção sistólica relacionada à cardiotoxicidade (NCT01724450) / Background: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Its prevention with beta-blockers remains controversial. The aim of this prospective, randomized, double-blind, placebo-controlled study was to evaluate the role of carvedilol in the prevention of early onset ANT cardiotoxicity. Methods: We randomized 200 patients with breast cancer and normal left ventricular ejection fraction (LVEF) referred for doxorubicin (240 mg/m²) to receive carvedilol or placebo until completion of chemotherapy. The primary end-point was a reduction > 10% in LVEF at six months. Secondary outcomes were the effects of carvedilol on troponin I (TnI), BNP and diastolic dysfunction. Results: Primary end-point occurred in 14 (14.5%) patients in the carvedilol and in 13 (13.5%) in the placebo (p=1.0). No difference in changes of LVEF or BNP was noted between groups. There was a significant difference between groups on the TnI levels over time, with lower TnI levels in carvedilol group (p=0.003). Additionally, a lower incidence of diastolic dysfunction was seen in carvedilol group (p=0.039). A trend towards less pronounced increase in LV end-diastolic diameter during follow up was noted in the carvedilol group, respectively 44.1+3.64 to 45.2+3.2 vs 44.9+3.6 to 46.4+4.0 mm (p=0.057). Conclusion: In this largest clinical trial of ?-blockers for prevention of early onset cardiotoxicity under contemporary doses of ANT, we noted a lower incidence of cardiotoxicity than higher doses. In this scenario, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction. However, this reduction had no impact on the incidence of cardiotoxicity-related myocardial systolic dysfunction (NCT01724450)

Esse estudo descreve casos de “morte súbita” em bovinos associados com a ingestão de Amorimia (Mascagnia) exotropica em seis propriedades rurais localizadas na região metropolitana de Porto Alegre e da serra gaúcha. Os bovinos intoxicados foram encontrados mortos sem história de sinais clínicos prévios, ou apresentaram tremores musculares, quedas bruscas, movimentos de pedalagem, opistótono, respiração ofegante e decúbito lateral, quando induzidos ao movimento poucos minutos antes da morte. Registrou-se maior número de casos entre os meses de maio e agosto. Nove bovinos foram necropsiados e os principais achados macroscópicos observados foram mucosa oral levemente cianótica (3/9), hidropericárdio leve a moderado (3/9), petéquias e equimoses no epicárdio (5/9), coágulo no interior do ventrículo esquerdo (4/9), edema pulmonar (5/9) e mucosas vermelhas no abomaso e no intestino delgado (6/9). Histologicamente havia necrose de coagulação no miocárdio (9/9) caracterizada por retração celular, aumento da eosinofilia do citoplasma com perda das estriações, núcleos em picnose e ocasionais núcleos em cariorrexia e cariólise. No coração, edema intersticial (3/9) e infiltrado inflamatório intersticial, predominantemente, mononuclear (7/9) também foram observados. Nos rins de três bovinos havia degeneração hidrópicovacuolar multifocal das células epiteliais dos túbulos contorcidos distais associada com núcleos picnóticos deslocados para periferia da célula. As lesões cardíacas desses bovinos foram demonstradas através da imuno-histoquímica para troponina cardíaca C (cTnC). Nos corações dos bovinos intoxicados ocorreu diminuição acentuada de cTnC no citoplasma de grupos dos cardiomiócitos com características microscópicas de degeneração e necrose e, em algumas áreas havia perda total de imunomarcação. Raras fibras musculares cardíacas sem alteração histológica apresentaram perda de imunomarcação. Nos demais cardiomiócitos dos bovinos intoxicados sem lesões histológicas observou-se intensa marcação citoplasmática. / This study describes cases of sudden death in cattle that were associated with the consumption of Amorimia (Mascagnia) exotropica and occurred in six ranches located in the mountainous region of Rio Grande do Sul and the metropolitan region of Porto Alegre, Brazil. Affected cattle were found dead with no history of previous clinical signs, or showed muscular tremors, falls, paddling, opistotonus, panting, and lateral recumbence after being induced to move, few minutes before death. Most cases were recorded between May and August. Nine cattle were necropsied and main gross findings were oral mucosa slightly cyanotic (3/9), mild to intermediate hydropericardium (3/9), epicardial petechiae and ecchymoses (5/9), clot within the left ventricle (4/9), lung edema (5/9), apart of abomasal and small intestinal reddened mucosa (6/9). Histologically, there was myocardial coagulation necrosis (9/9), which was characterized by cellular retraction, enhanced cytoplasmic eosinophilia, lack of cytoplasmic striations and occasional nuclear karyorrhexis and karyolysis. There also were interstitial edema (3/9) and interstitial inflammatory infiltrate (mainly mononuclear) (7/9) in the heart. Apart of multifocal vacuolar-hydropic degeneration in the epithelial cells of the distal convoluted tubules associated with pyknotic and eccentric nuclei in the kidneys of three cattle. The cardiac lesions of these cattle were demonstrated by immunohistochemistry for cardiac troponin C (cTnC). In the hearts of cattle intoxicated was severe reduction of the cTnC in the cytoplasm of cardiomyocytes groups with microscopic features of degeneration and necrosis, and in some areas with complete loss of immunoreactivity. Rare cardiac muscle fibers showed no histological abnormality loss of immune-marking. In the remaining cardiomyocytes in cattle poisoned histological lesions were absent, but an intense cytoplasmic staining in these cells was observed.

A degeneração valvar crônica mitral (DVCM) é uma cardiopatia de alta prevalência na clínica médica de pequenos animais e acomete principalmente cães idosos de raças de pequeno porte. A fim de se acompanhar a evolução da insuficiência cardíaca (IC), a galectina-3 (Gal-3) vem sendo utilizada como um biomarcador na identificação de doenças cardíacas pré-clínicas, progressão e descompensação em pacientes humanos. O objetivo deste estudo clínico foi estabelecer intervalos de referência da Gal-3 na população canina estudada e determinar a utilidade desse novo biomarcador sérico, isoladamente ou em associação com o pró-peptídeo natriurético tipo B (NT-proBNP) e a troponina cardíaca I (cTnI), para estimativa de prognóstico em curto prazo em cães com IC decorrente de DVCM. O delineamento fundamentou-se em um estudo clínico observacional transversal prospectivo com braço longitudinal. A amostra foi composta por 139 cães distribuídos em cinco grupos criteriosamente selecionados de acordo com o estadiamento da DVCM (Grupo controle: estágio A- composto por 60 cães hígidos de raças de pequeno porte com predisposição à DVCM, 28 cães em estágio B1, 20 cães em B2, 20 cães em estágio C e 11 cães em estágio D), advindos da rotina do Serviço de Cardiologia do VCM, Hospital Veterinário da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo. Os grupos B1, B2, C e D foram avaliados em um segundo momento, aos 60 dias. Foram dosados Gal-3 humana e canina, NTproBNP e cTnI. Os valores de referência mensurados no grupo A para Gal-3 humana foram de 7,548 ng/mL (P25%-75%=8,933-10,960). A recuperação da concentração de Gal-3 em cães clinicamente saudáveis, obtida com kit canino, foi significativamente mais baixa, com baixa repetibilidade e reprodutibilidade, em comparação com o kit humano, sugerindo assim menor sensibilidade do kit canino utilizado. Ainda, a magnitude e a variação nas concentrações de Gal-3 humana e canina não permitiram a detecção de diferenças entre os estágios da DVCM e também não foram capazes de identificar pacientes em IC. Conclui-se, portanto, que diferentemente dos demais marcadores avaliados, NT-proBNP e cTnI, já consagrados na IC para a espécie canina, a Gal-3 não se constitui em um biomarcador adequado para avaliar a IC secundária à DVCM em cães / Chronic mitral valve degeneration (CMVD) is a highly prevalent heart disease in small animal internal medicine seen mainly in older small breed dogs. In order to follow the progression of heart failure (HF), galectin-3 (Gal-3) has been applied as a biomarker to identify pre-clinical cardiac diseases, progression and decompensation in human patients. This study aimed to establish reference intervals for Gal-3 in a canine population, and to determine the utility of this new biomarker, isolated or in association with Type B natriuretic pro-peptide (NT-proBNP) and cardiac troponin I to estimate short term prognosis in dogs with HF caused by CMVD. It was designed as an observational prospective cross-sectional clinical study with a longitudinal arm. One hundred thirty nine dogs were distributed among five groups with rigorous selection criteria, according to ACVIM CMVD staging (Control group: stage A- 60 healthy small breed dogs, predisposed to CMVD; 28 dogs in stage B1, 20 dogs in stage B2, 20 dogs in stage C and 11 dogs in stage D), recruited from the Cardiology Service from the Veterinary Teaching Hospital, School of Veterinary Medicine, University of São Paulo. Groups B1, B2, C and D had a second blood sampling at day 60. Measurements were obtained for human and canine Gal-3, NT-proBNP and cTnI. Reference values obtained for group A for human Gal-3 were 7.548 ng/mL (P25%-75%=8.933-10.960). Gal-3 concentration recovery for healthy dogs obtained with canine kit was significantly lower, with low repeatability and reproducibility, compared to the human kit, suggesting lower sensitivity of the canine Gal-3 kit used. We concluded that the magnitude and variation observed in human and canine Gal-3 did not allow for detection of differences between stages of CMVD nor were capable of identifying patients in HF, compared to the other measured biomarkers, NT-proBNP and cTnI, already established for canine HF evaluation

Objetivo: Avaliar a relação entre os parâmetros da cardiotocografia computadorizada (cCTG) e da dopplervelocimetria com a lesão miocárdica fetal e com a ocorrência de acidemia no nascimento, em gestações com insuficiência placentária. Métodos: Estudo prospectivo com 49 gestações complicadas pela insuficiência placentária (Doppler de artéria umbilical anormal - índice de pulsatilidade [IP] > p95) diagnosticada entre 26 e 34 semanas. Todas as pacientes foram avaliadas pelo Doppler de artéria umbilical, artéria cerebral média e ducto venoso e pela cCTG (Sonicaid FetalCare, versão 2.2, por 30 minutos). Foi analisada a última avaliação fetal até 48h antes do parto e anterior à corticoterapia. Foi analisado o sangue de cordão umbilical no parto, para detectar a acidemia no nascimento (pH < 7,20) e a lesão miocárdica fetal (Troponina T cardíaca [cTnT] >= 0,09 ng/mL). A cTnT foi obtida em 38 casos e o pH em 46 casos. Resultados: Quinze (39,5%) recém-nascidos apresentaram cTnT >= 0,09 ng/ml e 20 (43,5%) pH < 7,20. Os fetos que evoluíram com acidemia apresentaram menor número de movimentos por hora na cCTG (mediana 2 vs. 15, p=0,019). Houve correlação positiva entre o pH e o número de movimentos fetais por hora (rho=0,35; P=0,019) e com a frequência cardíaca fetal basal (rho 0,37, P=0,011), e correlação negativa entre o pH e o escore zeta do IP para veias (IPV) do ducto venoso (rho= -0,31, P=0,036). A regressão logística identificou o escore-zeta do IPV do ducto venoso (P=0,023) e a frequência cardíaca fetal basal (P=0,040) como variáveis independentes associadas com a acidemia no nascimento. A ocorrência de lesão miocárdica fetal, quando comparada ao grupo com cTnT normal, apresentou associação significativa com o escore zeta do IP da artéria umbilical (mediana 8,8 vs. 4,0; P=0,003), IPV do ducto venoso (mediana 2,6 vs. -1,4; P= 0,007), frequência cardíaca fetal basal (mediana 146 vs. 139 bpm; P=0,033), número de acelerações entre 10-15 bpm (mediana 0 vs. 1; P=0,013), duração dos episódios de baixa variação (mediana 21 vs. 10 min; P=0,038) e a variação de curto prazo (short-term variation-STV) (mediana 3,7 vs. 6,1 ms; P=0,003). Observou-se correlação positiva entre o valor da cTnT no cordão umbilical e a frequência cardíaca fetal basal (rho=0,33; P=0,042), e correlação negativa entre a cTnT e a STV (rho= -0,37; P=0,021). A regressão logística identificou a STV como fator preditor independente para o dano miocárdico fetal (P=0,01), sendo a STV <= 4,3 ms o melhor ponto de corte para predição do evento (sensibilidade de 66,7% e especificidade de 91,3%). Conclusão: Em gestações com insuficiência placentária detectada antes da 34ª semana gestacional, o IPV do ducto venoso e a frequência cardíaca fetal basal analisada pela cCTG são os preditores independentes associados com a acidemia no nascimento; e o valor da STV avaliada pela cCTG é a variável que melhor prediz a lesão miocárdica fetal. A cCTG é ferramenta importante no manejo de fetos com insuficiência placentária, principalmente quando associada a outros métodos propedêuticos como a dopplervelocimetria / Objective: To evaluate the reliability of fetal heart rate parameters analyzed by computerized cardiotocography (cCTG) and fetal Doppler to predict myocardial damage and acidemia at birth in pregnancies complicated by placental insufficiency. Methods: Forty nine patients with placental insufficiency (abnormal umbilical artery Doppler - pulsatility index [PI] > p95) diagnosed between 26-34 weeks of gestation were prospectively studied. All patients were submitted to Dopplervelocimetry of umbilical artery, middle cerebral artery and ductus venosus and to the cCTG (Sonicaid Fetal Care, version 2.2; 30 minutes of duration). We analyzed the last fetal assessment 48h before delivery and prior to steroid therapy.Umbilical cord blood samples were collected at birth to detect acidemia (pH < 7.20) and myocardial damage (cTnT >= 0.09 ng/ml). The results of cTnT were available in 38 cases and in 46 cases we had the pH values. Results: Fifteen (39.5%) newborns had cTnT >= 0.09 ng/ml and 20 (43.5%) had a pH < 7.20. Fetuses who developed acidemia had fewer fetal movements per hour in cCTG (median 2 vs. 15, P=0.019). There was a positive correlation between pH and the number of fetal movements per hour (rho 0.35, P=0.019) and basal fetal heart rate (rho 0.37, P=0.011), and a negative correlation between pH and the zscore of pulsatility index for veins (PIV) of ductus venosus (rho= -0.31, P=0.036). The logistic regression analysis identified the z-score of PIV of ductus venosus (P=0.023) and basal fetal heart rate (P=0.040) as independent variables associated with acidemia at birth. The occurrence of fetal myocardial injury was significantly associated with z-score of PI of umbilical artery (median 8.8 vs. 4.0, P=0.003), PIV of ductus venosus (median 2.6 vs. -1.4, P=0.007), basal fetal heart rate (median 146 vs. 139 bpm, P=0.033), number of accelerations between 10-15 bpm (median 0 vs. 1, P=0.013), duration of episodes of low variation (median 21 vs. 10 min, P=0.038) and short-term variation (STV) (median 3.7 vs. 6.1 ms, P=0.003). We observed a positive correlation between the value of cTnT in the umbilical cord and basal fetal heart rate (rho=0.33, P=0.042), and a negative correlation between cTnT and STV (rho=-0.37, P=0.021). Logistic regression identified the STV as an independent predictor for myocardial damage (P=0.01), and STV <= 4.3 ms was the best cutoff to predict the event (sensitivity 66.7% and specificity of 91.3%). Conclusion: In pregnancies with placental insufficiency detected before the 34th week of gestation, the PIV of ductus venosus and basal fetal heart rate analyzed by cCTG are independent variables associated with acidemia at birth; and the STV is the parameter that best predicts fetal myocardial injury. The cCTG is an important tool in the management of fetuses with placental insufficiency, especially when associated with other diagnostic methods such as Doppler

Objetivo: Avaliar a relação entre os parâmetros da cardiotocografia computadorizada (cCTG) e da dopplervelocimetria com a lesão miocárdica fetal e com a ocorrência de acidemia no nascimento, em gestações com insuficiência placentária. Métodos: Estudo prospectivo com 49 gestações complicadas pela insuficiência placentária (Doppler de artéria umbilical anormal - índice de pulsatilidade [IP] > p95) diagnosticada entre 26 e 34 semanas. Todas as pacientes foram avaliadas pelo Doppler de artéria umbilical, artéria cerebral média e ducto venoso e pela cCTG (Sonicaid FetalCare, versão 2.2, por 30 minutos). Foi analisada a última avaliação fetal até 48h antes do parto e anterior à corticoterapia. Foi analisado o sangue de cordão umbilical no parto, para detectar a acidemia no nascimento (pH < 7,20) e a lesão miocárdica fetal (Troponina T cardíaca [cTnT] >= 0,09 ng/mL). A cTnT foi obtida em 38 casos e o pH em 46 casos. Resultados: Quinze (39,5%) recém-nascidos apresentaram cTnT >= 0,09 ng/ml e 20 (43,5%) pH < 7,20. Os fetos que evoluíram com acidemia apresentaram menor número de movimentos por hora na cCTG (mediana 2 vs. 15, p=0,019). Houve correlação positiva entre o pH e o número de movimentos fetais por hora (rho=0,35; P=0,019) e com a frequência cardíaca fetal basal (rho 0,37, P=0,011), e correlação negativa entre o pH e o escore zeta do IP para veias (IPV) do ducto venoso (rho= -0,31, P=0,036). A regressão logística identificou o escore-zeta do IPV do ducto venoso (P=0,023) e a frequência cardíaca fetal basal (P=0,040) como variáveis independentes associadas com a acidemia no nascimento. A ocorrência de lesão miocárdica fetal, quando comparada ao grupo com cTnT normal, apresentou associação significativa com o escore zeta do IP da artéria umbilical (mediana 8,8 vs. 4,0; P=0,003), IPV do ducto venoso (mediana 2,6 vs. -1,4; P= 0,007), frequência cardíaca fetal basal (mediana 146 vs. 139 bpm; P=0,033), número de acelerações entre 10-15 bpm (mediana 0 vs. 1; P=0,013), duração dos episódios de baixa variação (mediana 21 vs. 10 min; P=0,038) e a variação de curto prazo (short-term variation-STV) (mediana 3,7 vs. 6,1 ms; P=0,003). Observou-se correlação positiva entre o valor da cTnT no cordão umbilical e a frequência cardíaca fetal basal (rho=0,33; P=0,042), e correlação negativa entre a cTnT e a STV (rho= -0,37; P=0,021). A regressão logística identificou a STV como fator preditor independente para o dano miocárdico fetal (P=0,01), sendo a STV <= 4,3 ms o melhor ponto de corte para predição do evento (sensibilidade de 66,7% e especificidade de 91,3%). Conclusão: Em gestações com insuficiência placentária detectada antes da 34ª semana gestacional, o IPV do ducto venoso e a frequência cardíaca fetal basal analisada pela cCTG são os preditores independentes associados com a acidemia no nascimento; e o valor da STV avaliada pela cCTG é a variável que melhor prediz a lesão miocárdica fetal. A cCTG é ferramenta importante no manejo de fetos com insuficiência placentária, principalmente quando associada a outros métodos propedêuticos como a dopplervelocimetria / Objective: To evaluate the reliability of fetal heart rate parameters analyzed by computerized cardiotocography (cCTG) and fetal Doppler to predict myocardial damage and acidemia at birth in pregnancies complicated by placental insufficiency. Methods: Forty nine patients with placental insufficiency (abnormal umbilical artery Doppler - pulsatility index [PI] > p95) diagnosed between 26-34 weeks of gestation were prospectively studied. All patients were submitted to Dopplervelocimetry of umbilical artery, middle cerebral artery and ductus venosus and to the cCTG (Sonicaid Fetal Care, version 2.2; 30 minutes of duration). We analyzed the last fetal assessment 48h before delivery and prior to steroid therapy.Umbilical cord blood samples were collected at birth to detect acidemia (pH < 7.20) and myocardial damage (cTnT >= 0.09 ng/ml). The results of cTnT were available in 38 cases and in 46 cases we had the pH values. Results: Fifteen (39.5%) newborns had cTnT >= 0.09 ng/ml and 20 (43.5%) had a pH < 7.20. Fetuses who developed acidemia had fewer fetal movements per hour in cCTG (median 2 vs. 15, P=0.019). There was a positive correlation between pH and the number of fetal movements per hour (rho 0.35, P=0.019) and basal fetal heart rate (rho 0.37, P=0.011), and a negative correlation between pH and the zscore of pulsatility index for veins (PIV) of ductus venosus (rho= -0.31, P=0.036). The logistic regression analysis identified the z-score of PIV of ductus venosus (P=0.023) and basal fetal heart rate (P=0.040) as independent variables associated with acidemia at birth. The occurrence of fetal myocardial injury was significantly associated with z-score of PI of umbilical artery (median 8.8 vs. 4.0, P=0.003), PIV of ductus venosus (median 2.6 vs. -1.4, P=0.007), basal fetal heart rate (median 146 vs. 139 bpm, P=0.033), number of accelerations between 10-15 bpm (median 0 vs. 1, P=0.013), duration of episodes of low variation (median 21 vs. 10 min, P=0.038) and short-term variation (STV) (median 3.7 vs. 6.1 ms, P=0.003). We observed a positive correlation between the value of cTnT in the umbilical cord and basal fetal heart rate (rho=0.33, P=0.042), and a negative correlation between cTnT and STV (rho=-0.37, P=0.021). Logistic regression identified the STV as an independent predictor for myocardial damage (P=0.01), and STV <= 4.3 ms was the best cutoff to predict the event (sensitivity 66.7% and specificity of 91.3%). Conclusion: In pregnancies with placental insufficiency detected before the 34th week of gestation, the PIV of ductus venosus and basal fetal heart rate analyzed by cCTG are independent variables associated with acidemia at birth; and the STV is the parameter that best predicts fetal myocardial injury. The cCTG is an important tool in the management of fetuses with placental insufficiency, especially when associated with other diagnostic methods such as Doppler